A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Pfizer

Status: Enrolling

Conditions: Atopic Dermatitis

Treatments: Drug: CIBINQO

Study type: Observational

Funder types: Industry

Identifiers

NCT05387980

B7451055

Details and patient eligibility

About

The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Enrollment: 1,200 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants receiving this Product for treatment of AD.
2. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.

Exclusion criteria

1. Participants previously enrolled in this Study at the same site.

Trial design

1,200 participants in 1 patient group

Patients receiving CIBINQO

Description:

Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.

Treatment:

Drug: CIBINQO